Detalles de la búsqueda
1.
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Curr Atheroscler Rep
; 24(7): 585-597, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524914
2.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Am Heart J
; 231: 121-127, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33065120
3.
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
J Manag Care Spec Pharm
; 29(8): 952-964, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307087
4.
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Lancet
; 373(9667): 919-28, 2009 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19286091
5.
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Am Heart J
; 158(3): 335-341.e3, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19699854
6.
Factors affecting survival after heart transplantation: comparison of pre- and post-1999 listing protocols.
J Heart Lung Transplant
; 25(1): 42-7, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16399529
Resultados
1 -
6
de 6
1
Próxima >
>>